Skip to main content

Diabetes & Weight Loss News

Results from recent clinical trials have shown that GLP-1 receptor agonist medications are effective at lowering A1C and body weight.
Weight management is no easy task, but achieving and maintaining a healthy weight is important for your well-being, your diabetes management, and your overall health.
Weight impacts diabetes and diabetes impacts weight. The emotional and physical toll of excess weight is not exclusive to the type 2 diabetes community as diaTribe staff...
What can Type 1 University really teach you? See what type 1 maven Adam Brown has to say about Gary Scheiner's new brainchild.
Allergan’s LAP-BAND, an implantable weight-loss device. Following an FDA advisory committee ’s recommendation last December (see New Now Next in diaTribe #28), the FDA...
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.
(S)he said what?!?
We recently reviewed three drug candidates for the treatment of obesity – Contrave, lorcaserin, and Qnexa. All three drugs in development: they all have been submitted...
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
A next gen weight management and fitness tool— type 1 patient Adam Brown shares his thoughts on BodyMedia’s FIT Weight Management System.
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...
The LAP-BAND is a weight-loss device that is implanted around the top of the stomach using minimally invasive (laparoscopic) surgery, which effectively creates a small...
If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...
Recently, increasing evidence has suggested that weight-loss surgery (called “bariatric surgery”) can help improve type 2 diabetes management (or even cause its reversal...
In late November, the Centers for Medicare and Medicaid Services (the federal agency that administers the two public insurance programs) announced that Medicare would...
As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...
In late March, the International Diabetes Federation (IDF) released a "position statement" recommending the consideration of bariatric surgery to treat type 2 diabetes...

Pages